Kornimate/medical-research-clean huggingface dataset:
active living tool kit for chronic conditions

Conditions: Chronic Diseases

Summary: the development and pilot testing of a self-management program that would be delivered in a one time mailing.

the mailing will consist of (1) a self-test that will help users know how he or she can best use the materials and where to start; (2) a copy of the 2012 living healthy life with chronic conditions book. if people are visually impaired or have low literacy an audio cd of the book will be available in place of the print copy; (3)an exercise cd with flexibility and strengthening exercises at three different levels of intensity, designed for people with chronic conditions; (4) a relaxation cd with three different relaxation exercises; and (5) in addition, there will be tip sheets, one for each major tool such as managing pain, managing sleep, etc. it is expected that there will be 10-20 tip sheets in total. the key content of the self-test and the tip sheets will be developed surveying master trainers of the existing small-group chronic disease self management program (100 active trainers) and asking about 500 additional trainers to rank importance of key content items generated in initial survey. pilot testing of the program will be by 250 people with chronic diseases. participants will be surveyed by mailed questionnaires at baseline and six-months. a subgroup with diabetes (estimated 25-30%) will be asked to submit hemoglobin a1c blood test kits at baseline and six months.

Eligibility criteria:
inclusion criteria: * have a chronic health condition * 18 years of age * literate in english * (for the blood test subset): have type 2 diabetes exclusion criteria: * taken the small group or online chronic disease self management program or related programs * under 18 * active cancer treatment * pregnant

Keywords: chronic disease patient education self management
effects of a plyometric training program on youths with different biological maturity in sport

Conditions: Athletic Performance; Muscle Fatigue; Plyometric Exercise

Summary: this randomized controlled trial aims to assess the effectiveness of a 12-week plyometric training regimen on improving power, speed, and agility among boys aged 10 to 18 years who are actively engaged in sports and exhibit differing levels of biological maturity. the study seeks to determine how maturation affects the responsiveness to the training program, potentially influencing future sports training approaches for young athletes.

the main objective of this project is to assess the impact of a plyometric program on power, speed, agility, reactive strength index and stiffness in male athletes of different levels of maturation. the study takes the form of a short-term experiment (12 weeks), involving 30 young athletes with a minimum of two years of experience in systematic sports training. participants are divided into an experimental group and a control group. the experimental group undergoes a 12-week plyometric training program, implemented twice a week within training sessions immediately following warm-ups. the control group engages in technical-tactical exercises. the program is developed by the authors of the research project based on current knowledge and requirements for creating an effective and safe plyometric program. randomization is performed using a computer random generator. participants undergo two testing sessions: one prior to the training intervention and the other one week after its completion. age, height, weight, and body composition are measured using a personal scale with an integrated stadiometer. tests include a 30-m sprint, countermovement jump, broad jump, unilateral triple jump, drop jump (reactive strength index), 20 submaximal vertical jumps (lower limb stiffness), blazepod reaction test, and 505 agility test. the maturity status of the participants is evaluated using the mirwald method and is used as a covariate in the subsequent statistical analysis. findings of this research may provide crucial insights for targeted integration of plyometric methods during the developmental and maturation phases of young athletes.

Eligibility criteria:
inclusion criteria: * minimum of 2 years of organized sports participation. * good health as confirmed by a pre-study medical screening. * signed informed consent from the legal representative and verbal assent from the participant. exclusion criteria: * any serious lower limb injury in the past 6 months. * any current or historical mental health disorders. * any condition deemed by the medical screener as a contraindication to vigorous physical activity.
randomized-controlled trial of a combined vs. conventional percutaneous intervention for near-infrared spectroscopy defined high-risk native coronary artery lesions

Conditions: Arteriosclerosis; Near-infrared Spectroscopy; Peri-procedural Myocardial Infarction; Coronary Artery Disease

Summary: design: single center, single-blind randomized controlled trial of patients with high risk native coronary artery lesions (defined as ≥2 contiguous yellow blocks on the block chemogram) requiring clinically indicated percutaneous coronary intervention. patients will be randomized to either a combined intervention or conventional pci. cardiac biomarker measurements will be performed before pci and 18-24 hours later. treatment: combined intervention consisting of pre-pci intracoronary vasodilator and glycoprotein iib/iiia inhibitor administration, use of an epd if technically feasible, and complete coverage of the lipid core plaque, if technically feasible. control: conventional pci. duration: 30 days follow-up. the primary trial objective is to compare the incidence and size of periprocedural mi, as assessed by the peak post-pci troponin distribution in the two study groups. the secondary endpoints are: (1) reduction in the incidence of \>3x and \>10x upper limit of normal increase in ck-mb. (2) reduction in the incidence of slow flow/no-reflow post pci. (3) lower incidence of major adverse cardiac events, defined as the composite of death, acute coronary syndrome, or coronary revascularization) during 30-day follow-up.


Eligibility criteria:
inclusion criteria: 1. age ≥18 years. 2. willing and able to provide informed consent and able to comply with study procedures and follow-up. 3. undergoing a clinically indicated left heart coronary catheterization 4. need pci of a high-risk native coronary artery lesion. high-risk lesions will be defined as lesions with ≥2 contiguous yellow blocks on block chemogram. exclusion criteria: 1. coexisting conditions that limit life expectancy to less than 30-days or that could affect the patient's compliance with the protocol. 2. positive pregnancy test or breast-feeding. 3. high risk for bleeding. 4. subject is currently, or within the 30 preceding days, participating in a device or pharmaceutical treatment protocol. 5. clinical presentation with st-segment elevation mi. 6. persistent (\>10 minutes) hypotension (systolic blood pressure \<90 mmhg) 7. need for revascularization of multiple lesions during the index pci. 8. unprotected left main (\>50%) or equivalent left main disease.
ct data collection study

Conditions: Cardiac Disease

Summary: the primary objective of this study is to gather chest ct images as part of routine clinical procedure from subjects with and without prior sternotomy to characterize the substernal space. specifically, the study will provide references for physicians to better understand substernal anatomy.


Eligibility criteria:
inclusion criteria: * subject must be≥18 years old * subject must be indicated for high quality chest ct imaging as part of routine clinical procedure * subject must be willing to provide informed consent exclusion criteria: * subject has medical conditions that would limit study participation * subject is pregnant or have a pregnancy plan during the study * subject is enrolled in a concurrent study that may confound the results of this study
non-interventional study of the effect of smoking status of the patient on the success of etanercept therapy in psoriasis

Conditions: Plaque Psoriasis

Summary: pilot observational study to describe the relationship between the smoking status of a psoriatic individual and the success of etanercept therapy in psoriasis treatment

non-interventional study there is no sampling

Eligibility criteria:
inclusion criteria: clinical diagnosis of chronic plaque type psoriasis for at least 6 months as determined by the subjects medical history, and confirmation of the diagnosis through physical examination by the investigator patients who are scheduled by their dermatologist to initiate treatment with etanercept exclusion criteria: previous or current treatment with antipsoriatic biologic drugs, such as etanercept, infliximab, adalimumab, ustekinumab, alefacept, efalizumab chronic or acute infections requiring intravenous or oral anti-infectives within 14 days prior to the baseline visit

Keywords: plaque psoriasis smoking etanercept
safety and efficacy of bone marrow derived autologous cells treatment of cerebral palsy in subjects above 15 years

Conditions: Ataxic Infantile Cerebral Palsy

Summary: this study is single arm, single centre trial to study the safety and efficacy of bone marrow derived autologous mononuclear cells (100 millions per dose)study enrollment duration 36 months sample size 100 patients should be treated (above 15 years of age) with cerebral palsy in india. primary outcome measures are improvement in walking ability and kinetic gait pattern.

cerebral palsy is commonest cause of disability in india and south east asia. this study is devised to quantify the safety and efficacy of bone marrow derived autologous mononuclear cells(100 millions per dose)study enrolment duration 36 months sample size 100 patients should be treated (above 15 years of age) with cerebral palsy, in india. primary outcome measures are improvement in walking ability and kinetic gait pattern as per as various clinical scales and also changes in the brain.

Eligibility criteria:
inclusion criteria: * subject aged above 15 years with a diagnosis of cerebral palsy. regional nerve damage as shown by magnetic resonance imaging(mri) * patient suffer from cerebral palsy due to prenatal and postnatal cause, * willing to undergoing bone marrow derived autologous stem cell therapy. * able to comprehend and give written informed consent form for the study * willing to come to the hospital for follow up visits as per the protocol requirements exclusion criteria: * history of meningitis,meningoencephalitis , epilepsy or life threatening allergic or immune -mediated reaction * hemodynamically unstable patients * history of or concurrent autoimmune disease or acute episode if guillain- barre syndrome * peripheral muscular dystrophy

Keywords: ataxic infantile cerebral palsy stem cell therapy
the safety and efficacy of dexloxiglumide for the relief of symptoms of functional dyspepsia.

Conditions: Dyspepsia

Summary: "functional dyspepsia" has been defined loosely as "pain or discomfort centered in the upper abdomen." the symptoms can also include fullness, early satiety, bloating, belching, nausea, retching and vomiting. these symptoms may present with or without the co-existence of symptoms of heartburn or gastroesophageal reflux disease (gerd). functional dyspepsia is a diagnosis of exclusion in which other disease states, such as ulcer, cancer, etc. are ruled out and the source of the pain is unknown. the standard of care for most patients presenting with dyspeptic symptoms has been with proton pump inhibitors (ppi), regardless of whether or not the patient's symptoms include acid-related conditions, e.g., heartburn, gerd, etc. although ppi treatment has yielded some success in these patients, there is a significant population of patients whose dyspeptic symptoms are not adequately treated with ppi's alone. the purpose of this study is to evaluate the use of dexloxiglumide in the treatment of the symptoms of functional dyspepsia in patients whose dyspeptic symptoms are not being treated adequately with ppi's.


Eligibility criteria:
inclusion criteria: * be male or female, 18 to 75 years of age, inclusive. * must understand english and be able to follow the instructions about completing the diary and questionnaires. * at the time of screening, have pain and/or discomfort in your upper abdomen for at least one day each week in the last month. * at the time of screening, have at least one other symptom of fd for at least one day each week in the last month. exclusion criteria: * have a known hypersensitivity to dexloxiglumide, any ppi, or aluminum/magnesium-containing antacids * have a history of organic diseases, structural or biochemical, of the gastrointestinal system that can cause dyspepsia. * have active irritable bowel syndrome (c-ibs, alt-ibs, d-ibs). * have findings leading to a clinical suspicion of other secondary causes of dyspepsia, including endocrine, metabolic and neurological disorders. * have a body mass (bmi) value of greater than 38 (applies to both males and females). * have been enrolled in a previous investigational study of dexloxiglumide. * have received treatment with any investigational drug within a 30-day period, or 5 half-lives, whichever is longer, prior to study entry. * use or dependence on "prohibited" medications at study entry.

Keywords: functional dyspepsia cholecystokinin cck gastrointestinal intestinal transit gi motility bloating upper gi discomfort upper gi early satiety nausea belching retching vomiting gerd
lidocaine for neuroprotection during cardiac surgery

Conditions: Cognitive Decline

Summary: the purpose of this study is to see if a drug called lidocaine prevents cognitive injury (a decline in mental abilities) after heart surgery. lidocaine is currently fda approved and is commonly used for treating some heart rhythm disorders and for regional anesthesia (blocking nerves). the investigators are enrolling subjects in this research project to see if lidocaine will reduce the high incidence of cognitive injury seen after heart surgery. as part of this study, the investigators will also evaluate the relationship between cognitive injury and genetic makeup and the chemical changes in the subjects blood during and after surgery.


Eligibility criteria:
inclusion criteria: 1. cabg, cabg + valve, or valve surgery 2. use of cardiopulmonary bypass exclusion criteria: 1. less than 50 years of age 2. history of diabetes 3. history of symptomatic cerebrovascular disease (e.g. prior stroke) with residual deficit 4. alcoholism (\> 2 drinks/day) 5. history of psychiatric illness (any clinical diagnoses requiring therapy) 6. history of drug abuse (any illicit drug use in the past 3 months) 7. hepatic insufficiency (liver function tests \> 1.5 times the upper limit of normal) 8. severe pulmonary insufficiency (requiring home oxygen therapy) 9. renal failure (baseline serum creatinine \> 2.0 mg/dl) 10. pregnant women 11. unable to read and thus unable to complete the cognitive testing 12. score \< 24 on a baseline mini mental state examination (mmse) or greater than or equal to 27 on the baseline center for epidemiological studies depression (ces-d) scale -

Keywords: cognition
high- versus low-calcium water for bone health

Conditions: Orthopedic Disorder; Calcium Metabolism Disorders; Bone Resorption; Water-Electrolyte Imbalance; Eating, Healthy

Summary: the experimental study investigates which metabolic responses of calcium and parathyroid hormone are observable in blood and urine in a cohort of 41 healthy adults following a sequence of different exposures: low-calcium water first and high-calcium water afterward.


Eligibility criteria:
inclusion criteria: * body mass index ≥ 18 and \< 30 * maintenance of diet and physical activity lifestyle throughout the duration of the study * acceptance of informed consent exclusion criteria: * consumption of water with calcium \> 150 mg/l * pregnancy (as established by self-declaration), breastfeeding, menopause * inability to follow the study protocol * cardiac, vascular, renal, and oncological disease * neuropsychiatric disease, developmental disorders * disease or past surgery affecting the gastrointestinal tract * drugs that interfere with bone (e.g. corticosteroids) or with fluid balance (e.g. diuretics)
gene expression profiling in pbmcs as a tool for prediction of infliximab responsiveness in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the objective of the study is to identify and validate predictive markers of infliximab responsiveness in ra patients by 2 approaches: i) measuring biochemical, immunological and bone markers in sera because of their involvement in pathogenic mechanisms; ii) identifying gene-expression signatures in pbmcs by the transcriptomic analysis. patients with active ra (acr criteria) were given i.v. 3 mg/kg infliximab associated with metotrexate at weeks 0, 2, 6, and every 8th week. infliximab efficacy was evaluated at week 14, using the eular response criteria. 1. just before the starting of infliximab treatment, the following parameters were measured in the sera: i) immunological tests: rheumatoid factor (iga, igg, igm), anti-ccp, autoab recognizing the 27 c-terminal fragment (acast-c27) and domain i (acast-di) of calpastatin, anti-g6pi, anti a-enolase, anti-keratin and anti-perinuclear factor; ii) biochemical markers: crp, mmp-1, mmp-3, timp-1, timp-2; markers of bone resorption: pyridinolin, deoxypyridinolin, osteoprotegerin, srankl, comp. the predictive value of each parameter for a response/non-response to infliximab was analysed using fischer's exact, mann-whitney and chi2 tests. 2. a blood sample was collected just before the onset of infliximab treatment and total rnas were extracted from the peripheral blood mononuclear cells. the \[33p\] radiolabeled mrnas were hybridized (duplicate or triplicate) over a set of 10.000 human cdna probes spotted at a high density on nylon membranes. data were normalized and filtered to allow the comparison between rna samples. statistical analyses were performed with the r software and hierarchical clustering was performed with the cluster and tree view softwares.


Eligibility criteria:
inclusion criteria: * is age 18 years old or older satisfies the 1987 american college of rheumatology revised criteria for rheumatoid arthritis has active disease at the time of randomization as indicated by a das28\> 5.1 has a disease at least refractory to dmards whose methotrexate or leflunomide is capable of understanding and signing an informed consent form agrees to use a medically accepted form of contraception during the study exclusion criteria: * is pregnant or breast-feeding or without has significant concurrent medical diseases including cancer or a history of cancer within 5 years of entering the study, uncompensated congestive heart failure, significant active infection or any underlying diseases that could predispose subjects to infections (whose tuberculosis) has allergy to infliximab
prevalence of dyschromatopsia in glaucoma patients

Conditions: Open Angle Glaucoma

Summary: glaucoma is a progressive disease resulting in loss of retinal nerve cells and their axons (retinal nerve fibers). retinal nerve fibers are ordered in a special manner when they enter the optic nerve. hence, damage to the retinal nerve fibers by glaucoma results in visual field defects at certain locations. furthermore, the retinal nerve fiber layers from different receptors for different colors are ordered in a special manner as well. thus, it is possible that glaucomatous damage causes color vision dysfunction (dyschromatopsia). at the moment there is disagreement whether dyschromatopsia occurs at early- to mid-stage or only in end-stage glaucoma. by testing color vision in glaucoma patients the prevalence of dyschromatopsia in glaucoma and in different stages of the disease will be investigated.


Eligibility criteria:
inclusion criteria: * diagnosis of open angle glaucoma * visual acuity \>/= 20/50 * age \>/= 18 (no upper limit) * male or female gender exclusion criteria: * other type of glaucoma * age \<18 * other retinal disease (e.g. age related macular degeneration) * other disease affecting the optic nerve or the retinal nerve fibers * known color blindness

Keywords: oag
open label study to assess the predictability of early response to certolizumab pegol in patients with rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the study aims to evaluate the predictability of early response to certolizumab pegol in combination with methotrexate at one year in patients with moderate to severe rheumatoid arthritis.


Eligibility criteria:
inclusion criteria: * diagnosis of adult-onset rheumatoid arthritis (ra) for a duration of at least 6 months but not longer than 5 years * positive rheumatoid factor (rf) and/or positive anti cyclic citrullinated peptide (anti-ccp) * active ra disease * subjects must have failed at least one traditional disease modifying anti-rheumatic drug (dmard). * subject is naïve to ra related biologics exclusion criteria: * a diagnosis of any other inflammatory arthritis * history of infected joint prosthesis, or other significant infection * known tuberculosis (tb) disease or high risk of acquiring tb infection

Keywords: certolizumab pegol - cimzia rheumatoid arthritis power doppler ultrasonography italy moderate-severe rheumatoid arthritis
an evaluation of the nighttime retention of effect of an investigational lubricant eye drop (fid 115958d)

Conditions: Dry Eye

Summary: the purpose of this study is to describe the night-time use of an investigational lubricant eye drop.


Eligibility criteria:
inclusion criteria: 1. documented diagnosis of dry eye 2. current use of an eye ointment or tube gel exclusion criteria: 1. no nighttime contact lenses wear throughout the study period 2. must not have had punctal plugs inserted within 30 days preceding enrollment

Keywords: dry eye artificial tears
hybrid training and middle age

Conditions: Women's Health; Hybrid Training; Middle Aged; Non-alcoholic Fatty Liver Disease; Metabolic Syndrome

Summary: modern living and physical inactivity results in many ailments, including obesity, non-alcoholic fatty liver disease (nafld), and inflammatory issues. though there are a lot of studies on physical training, there is little detail on hybrid training or electrical and voluntary contractions of the musculature. this study investigated the efficiency of hybrid training in biochemistry, ultrasound, and proinflammatory outcomes in middle-aged sedentary and obese women with nafld.


Eligibility criteria:
inclusion criteria: * sedentary women with one to two exercise sessions or less per month * bmi equal to or above 30 kg/m-2 * whr equal or above 0.85 m * confirmed nafld, with grade 2 and 3 * systolic blood pressure not less than 130 mm hg and diastolic blood pressure not less than 85 mm hg * increased ast and alt * mean age 45-65 years exclusion criteria: * use of 140 grams or more of ethanol per week * history of depression in the last 6 months * history of chronic or acute viral hepatitis * drug-related liver disease and chronic liver disease * history of diabetes * uncontrolled hypertension * myocardial infarction * chronic kidney disease * hyperthyroidism or heart failure * those who have weight loss programs or medical contraindications for physical training * serious arterial hemorrhagic disorders * serious neurological diseases * advanced atherosclerosis * elevated fever